- Home
- UBX vs CXAI Comparison
UBX vs CXAI Comparison
Compare UBX & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- CXAI
- Stock Information
- Founded
- UBX 2009
- CXAI N/A
- Country
- UBX United States
- CXAI United States
- Employees
- UBX N/A
- CXAI N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- CXAI EDP Services
- Sector
- UBX Health Care
- CXAI Technology
- Exchange
- UBX Nasdaq
- CXAI Nasdaq
- Market Cap
- UBX 20.4M
- CXAI 22.4M
- IPO Year
- UBX 2018
- CXAI N/A
- Fundamental
- Price
- UBX $0.99
- CXAI $1.13
- Analyst Decision
- UBX Strong Buy
- CXAI
- Analyst Count
- UBX 3
- CXAI 0
- Target Price
- UBX $5.33
- CXAI N/A
- AVG Volume (30 Days)
- UBX 148.7K
- CXAI 6.2M
- Earning Date
- UBX 04-22-2025
- CXAI 04-07-2025
- Dividend Yield
- UBX N/A
- CXAI N/A
- EPS Growth
- UBX N/A
- CXAI N/A
- EPS
- UBX N/A
- CXAI N/A
- Revenue
- UBX N/A
- CXAI $7,142,000.00
- Revenue This Year
- UBX N/A
- CXAI $114.23
- Revenue Next Year
- UBX N/A
- CXAI N/A
- P/E Ratio
- UBX N/A
- CXAI N/A
- Revenue Growth
- UBX N/A
- CXAI N/A
- 52 Week Low
- UBX $0.85
- CXAI $0.76
- 52 Week High
- UBX $3.10
- CXAI $5.43
- Technical
- Relative Strength Index (RSI)
- UBX 37.79
- CXAI 53.40
- Support Level
- UBX $0.91
- CXAI $1.03
- Resistance Level
- UBX $1.07
- CXAI $1.12
- Average True Range (ATR)
- UBX 0.09
- CXAI 0.17
- MACD
- UBX 0.03
- CXAI 0.02
- Stochastic Oscillator
- UBX 61.29
- CXAI 49.22
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.